Compare IDXX & NDAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDXX | NDAQ |
|---|---|---|
| Founded | 1983 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2B | 51.5B |
| IPO Year | 1991 | 2002 |
| Metric | IDXX | NDAQ |
|---|---|---|
| Price | $697.82 | $94.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $700.50 | $102.07 |
| AVG Volume (30 Days) | 587.0K | ★ 3.6M |
| Earning Date | 02-02-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.14% |
| EPS Growth | 21.65 | ★ 66.50 |
| EPS | ★ 12.60 | 2.80 |
| Revenue | $4,167,411,000.00 | ★ $8,168,000,000.00 |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $8.79 | $7.75 |
| P/E Ratio | $55.32 | ★ $33.83 |
| Revenue Growth | 8.39 | ★ 16.40 |
| 52 Week Low | $356.14 | $64.84 |
| 52 Week High | $769.98 | $97.63 |
| Indicator | IDXX | NDAQ |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 71.05 |
| Support Level | $687.68 | $92.18 |
| Resistance Level | $711.68 | $95.86 |
| Average True Range (ATR) | 15.97 | 1.54 |
| MACD | -4.71 | 0.41 |
| Stochastic Oscillator | 18.40 | 90.58 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.